X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NOVARTIS - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NOVARTIS AUROBINDO PHARMA/
NOVARTIS
 
P/E (TTM) x 18.2 351.0 5.2% View Chart
P/BV x 5.9 17.3 34.3% View Chart
Dividend Yield % 0.4 1.7 21.0%  

Financials

 AUROBINDO PHARMA   NOVARTIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
NOVARTIS
Mar-16
AUROBINDO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,541982 156.9%   
Low Rs582556 104.6%   
Sales per share (Unadj.) Rs237.5252.9 93.9%  
Earnings per share (Unadj.) Rs33.962.1 54.5%  
Cash flow per share (Unadj.) Rs40.663.3 64.1%  
Dividends per share (Unadj.) Rs2.5010.00 25.0%  
Dividend yield (eoy) %0.21.3 18.1%  
Book value per share (Unadj.) Rs120.6363.6 33.2%  
Shares outstanding (eoy) m585.1731.96 1,830.9%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.53.0 147.0%   
Avg P/E ratio x31.312.4 253.2%  
P/CF ratio (eoy) x26.212.2 215.2%  
Price / Book Value ratio x8.82.1 416.1%  
Dividend payout %7.416.1 45.9%   
Avg Mkt Cap Rs m621,04124,580 2,526.6%   
No. of employees `00013.30.8 1,767.0%   
Total wages/salary Rs m15,5081,801 861.0%   
Avg. sales/employee Rs Th10,457.610,748.9 97.3%   
Avg. wages/employee Rs Th1,167.12,395.2 48.7%   
Avg. net profit/employee Rs Th1,491.62,641.1 56.5%   
INCOME DATA
Net Sales Rs m138,9618,083 1,719.1%  
Other income Rs m1,663829 200.5%   
Total revenues Rs m140,6248,913 1,577.8%   
Gross profit Rs m32,056234 13,687.3%  
Depreciation Rs m3,92637 10,697.8%   
Interest Rs m2,5682 142,644.4%   
Profit before tax Rs m27,2251,025 2,655.8%   
Minority Interest Rs m390-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m7,444752 989.9%   
Profit after tax Rs m19,8201,986 997.9%  
Gross profit margin %23.12.9 796.2%  
Effective tax rate %27.373.4 37.3%   
Net profit margin %14.324.6 58.0%  
BALANCE SHEET DATA
Current assets Rs m100,01512,678 788.9%   
Current liabilities Rs m74,7592,433 3,072.7%   
Net working cap to sales %18.2126.7 14.3%  
Current ratio x1.35.2 25.7%  
Inventory Days Days10733 328.5%  
Debtors Days Days11022 487.3%  
Net fixed assets Rs m52,35069 75,650.7%   
Share capital Rs m585160 366.2%   
"Free" reserves Rs m67,70711,460 590.8%   
Net worth Rs m70,56711,621 607.2%   
Long term debt Rs m8,4720-   
Total assets Rs m156,99414,400 1,090.3%  
Interest coverage x11.6570.5 2.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.90.6 157.7%   
Return on assets %14.313.8 103.3%  
Return on equity %28.117.1 164.3%  
Return on capital %37.723.6 160.1%  
Exports to sales %51.00.7 6,853.4%   
Imports to sales %18.818.6 101.4%   
Exports (fob) Rs m70,92760 117,818.6%   
Imports (cif) Rs m26,1931,503 1,743.1%   
Fx inflow Rs m71,015186 38,118.7%   
Fx outflow Rs m28,7991,821 1,581.7%   
Net fx Rs m42,216-1,635 -2,582.8%   
CASH FLOW
From Operations Rs m17,5962,531 695.2%  
From Investments Rs m-13,801-8,270 166.9%  
From Financial Activity Rs m-198-386 51.4%  
Net Cashflow Rs m3,597-6,125 -58.7%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 2.0 397.5%  
FIIs % 27.7 1.6 1,731.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.5 47.4%  
Shareholders   69,601 41,647 167.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS